Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.16 Bil Enterprise Value: 9.58 Bil PE Ratio: 106.36 PB Ratio: 2.73 GF Score: 85/100

Qiagen NV at Jefferies London Healthcare Conference Transcript

Nov 16, 2022 / 08:10AM GMT
Release Date Price: €47.05 (-1.66%)
Peter James Welford
Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst

My name is Peter Welford. I'm the European pharma biotech and life sciences analyst at Jefferies in London. My pleasure to be hosting the next company in this track, which is QIAGEN. Here from QIAGEN, we have the CFO, standing up there, Roland Sackers; and we also have Phoebe Loh from IR as well with me on the table. It's a fireside chat. Roland is going to make a few introductory remarks, and then we'll open for Q&A. (Operator Instructions)

We'd love to get questions if you do have them. But with that, over to you, Roland. Thank you.

Roland Sackers
Qiagen N.V. - CFO, MD & Member of Management Board

Yes. And thanks, Peter. Thanks for having us. It's always good to see you again and have physical meetings. It clearly makes a difference even if sometimes carry too many people in small hotel rooms, but it's a different story.

Nevertheless, you might have seen that we just last week released results, and we had a very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot